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OBJECTIVES: This study sought to assess the adherence of newly diagnosed hepatocellular carcinoma patients to
the Barcelona Clinic Liver Cancer system treatment guidelines and to examine the impact of adherence on the
survival of patients in different stages of the disease.
METHODS: This study included all patients referred for the treatment of hepatocellular carcinoma between
2010 and 2012. Patients (n=364) were classified according to the Barcelona Clinic Liver Cancer guidelines. Devia-
tions from the recommended guidelines were discussed, and treatment was determined by a multidisciplinary
team. The overall survival curves were estimated with the Kaplan-Meier method and were compared using the
log-rank test.
RESULTS: The overall rate of adherence to the guidelines was 52%. The rate of adherence of patients in each
scoring group varied as follows: stage 0, 33%; stage A, 45%; stage B, 78%; stage C, 35%; and stage D, 67%. In
stage 0/A, adherent patients had a significantly better overall survival than non-adherent patients (hazard
ratio=0.19, 95% confidence interval (CI): 0.09–0.42; po0.001). Among the stage D patients, the overall survival
rate was worse in adherent patients than in non-adherent patients (hazard ratio=4.0, 95% CI: 1.67–9.88;
po0.001), whereas no differences were observed in patients in stages B or C.
CONCLUSIONS: The rate of adherence to the Barcelona Clinic Liver Cancer staging system in clinical practice
varies according to clinical disease stage. Adherence to the recommended guidelines positively impacts survival,
especially in patients with early-stage disease.
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’ INTRODUCTION
Hepatocellular carcinoma (HCC) has a high mortality rate
and is one of the most common cancers worldwide. The inci-
dence of HCC has continued to increase, and an estimated
782,000 new cases occurred in 2012 (1,2). The management
of HCC patients is complex because of the association of
this cancer with chronic liver disease (3). The treatment and
staging of HCC depend on the evaluation of tumor char-
acteristics, liver function, and patient status.
Clinical practice guidelines have an important role in guid-
ing and standardizing disease management. The Barcelona
Clinic Liver Cancer (BCLC) staging system, which is used to
guide the treatment of patients with HCC, was first intro-
duced in 1999 and was most recently updated in 2012. This
classification is considered a complete and accurate staging
system because it not only evaluates tumor characteristics,
performance status, and liver function but also links disease
staging to treatment (4–7). However, the clinical application
of such a staging system is challenging due to the variability
in patient profiles and accessibility to certain treatments,
such as liver transplantation.
Adherence to BCLC recommendations has been evaluated
in some studies, but the impact of adherence on patient survival
has only been evaluated in two studies with conflicting
conclusions (8–11). Therefore, this study sought to comprehen-
sively evaluate the overall survival (OS) of newly diagnosed
HCC cases according to BCLC adherence and examine the
impact of treatments performed at various disease stages.DOI: 10.6061/clinics/2017(08)01
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This retrospective study considered all patients who were
referred to the Instituto do Câncer do Estado de São Paulo
between May 2010 and May 2012 for HCC treatment. Only
those patients with a newly confirmed diagnosis of HCC
according to the American Association for the Study of Liver
Diseases guidelines (5) and who had not previously been
treated for HCC were included in the study. During this
period, 383 patients were evaluated, and 19 patients were
excluded for the following reasons: diagnosis of fibrolamellar
HCC (n=3), incomplete tumor or patient data (n=2), or
unconfirmed HCC diagnosis (n=14). Thus, 364 patients had
sufficient available data for a comprehensive analysis and
were included in the study.
The study protocol conformed to the ethical guidelines of
the 1975 Declaration of Helsinki and was approved by the
Institutional Review Board of the University of Sao Paulo
School of Medicine.
HCC evaluation
After the HCC diagnosis was confirmed, chest and abdo-
minal computed tomography scans and bone scintillography
were performed for HCC staging. The number and size of
the nodules, vascular invasion, and extrahepatic spread were
evaluated. The following clinical and biochemical data were
collected at the time of diagnosis: age, sex, Eastern Coope-
rative Oncology Group Performance Status (ECOG-PS),
etiology of liver disease, Child-Pugh class, Model for End-
stage Liver Disease (MELD) score, and serum alpha-
fetoprotein (AFP) level.
Adherence to BCLC recommendations
After this initial evaluation, the patients were classified
according to the BCLC staging system and were stratified
into five stages (0, A, B, C, and D) (7). The BCLC treatment
recommendations were initially considered for all patients by
the hepatology team. A multidisciplinary team, including
hepatologists, surgeons, radiologists, and oncologists, was
involved in discussions of any deviation from these recom-
mendations. The reason for the choice of treatment was
reported in the clinical record, and the final decision was
discussed with each patient. Informed consent was obtained
from all patients before they received treatment.
The primary endpoint was OS. Survival time was defi-
ned as the interval between the date of diagnosis and either
death or the last follow-up visit. This study was censored on
May 31, 2014.
Statistical analysis
Patient characteristics are presented with descriptive
statistics, and continuous variables are expressed as the
means±SD or medians (range). Data were analyzed using R
statistical software, version 3.1.2 (12). Cutoffs for continuous
variables were obtained by maximizing the log-rank statistic.
The OS curves were estimated with the Kaplan-Meier sur-
vival method and were compared using the log-rank test;
median survival times and their 95% confidence intervals
(CIs) are also reported. The significance of variables for the
prediction of OS rate was assessed by a multivariate Cox
proportional hazard regression analysis. Proportional hazard
assumption was verified through Schoenfeld residuals.
A po0.05 was considered significant.
’ RESULTS
The baseline clinical and laboratory characteristics are
summarized in Table 1. A total of 189/364 (52%) patients
were eligible for and received the BCLC-recommended
therapies. However, the rate of adherence varied among
patients with different disease stages (Figure 1). The highest
rates of adherence were found in patients with BCLC stages
B and D, whereas the lowest rates were found in patients
with stages 0, A, and C.
HCC treatment and reasons for discrepancy
BCLC 0/A patients. Twenty-three patients were eligible
for resection. In this group, only one patient was classified at
a very early stage. Eight of the 23 patients (35%) underwent
resection, which was contraindicated due to tumor location
(n=12) and the presence of a comorbidity (n=3); these
patients were treated with percutaneous therapy (PT; n=7)
and transarterial chemoembolization (TACE; n=8).
Eighty-three patients in this group were considered for
liver transplantation, and 36/83 (43%) finally received a
cadaveric liver transplantation. Of these patients, all but
three received bridge therapy with TACE (n=16) or PT (n=17)
during the 15-mo waiting period. Transplantation was not
performed in the other patients for the following reasons:
patient refusal (n=5), comorbidities (e.g., other malignancies,
drug abuse, HIV, or cardiac or pulmonary disease) (n=11),
death while on the wait list (n=14), surgical resection per-
formed despite portal hypertension (as liver function was
preserved, and the wait time for transplantation was too
long) (n=4), or other reasons (n=4). At the end of the study,
nine patients were still on the liver transplant list.
Ablative PTwas the recommended first-line treatment for
24 patients with very early- and early-stage HCC, and of
these patients, 13 (54%) finally received radiofrequency abla-
tion (RFA) or percutaneous ethanol injection (PEI). For the
remaining 11/24 (46%) patients, the tumor location was a
contraindication, and TACE was performed (n=10).
BCLC B patients. TACE was the BCLC treatment
recommendation for the 85 patients with stage B disease,
and of these patients, 67 (79%) were treated using this
approach. Five patients with a single nodule 45 cm and
compensated liver function without clinical signs of portal
hypertension underwent resection. One patient received a
living-donor liver transplant, two patients were treated with
RFA, and ten received best supportive care because of
comorbidities and/or disease progression.
BCLC C patients. Only 41/115 (36%) stage C patients
received BCLC-recommended sorafenib treatment. Thirty-
seven patients without vascular invasion or extrahepatic
spread who were classified as BCLC C because of compro-
mised performance status (ECOG 1–2) received HCC the-
rapy according to the number and size of tumors as follows:
liver transplant (n=2), resection for a single nodule without
portal hypertension (n=5), RFA or PEI (n=9), or TACE for
large or multifocal HCC (n=28). Thirty BCLC C patients who
were not suitable for any conventional or experimental
treatments due to tumor features or liver failure received best
supportive care.
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BCLC D patients. Twenty-three of the 34 (68%) patients
with stage D disease were managed with best supportive
care. Non-adherence was reserved for patients who met the
Milan criteria for liver transplant (n=11). Two patients recei-
ved transplants by the end of the follow-up period, and
super-selective TACE (n=7) and RFA (n=2) were provided to
those on the wait list.
Follow-up
The median follow-up period was 19.0 mo (95% CI, 0.5–
52.0 mo) for the entire group. At the time of censoring, 217/
364 (59%) patients had died. Most (150/217, 69%) of the
deaths were tumor-related. Other causes of death included
liver failure (n=42) and therapy-related complications (n=19).
Some causes of death were not related to tumor progression
or liver failure and were censored (n=6).
Survival
The one-, two-, and three-year OS rates were 63, 45,
and 33%, respectively. A univariate analysis identified the
following as significant contributing factors: age, Child-
Pugh classification, MELD score, serum AFP level, ECOG-
PS, tumor size, number of tumors, presence of vascular
invasion, extrahepatic spread, and BCLC classification (all
po0.05) (Table 2). Factors with a po0.10 were selected for
inclusion in a multivariate analysis, which showed that
age 466 years, Child-Pugh B/C, MELD411, ECOG-PS40,
AFP level 4100 ng/mL, tumor size 450 mm, vascular
invasion, and extrahepatic spread remained significant factors
of OS.
Survival and adherence to BCLC recommendations.
Overall, no difference was observed in OS between patients
according to adherence to BCLC recommendations. The
one-, two-, and three-year OS rates were 63, 52, and 30%,
respectively, for the adherent group, and 62, 38, and 30%,
respectively, for the non-adherent group. However, signifi-
cant differences were found among patients with various
BCLC disease stages (Figure 2). BCLC stage 0/A patients
who adhered to the BCLC recommendations had better OS
rates than those of the patients in the non-adherent group
(HR=0.19, 95% CI: 0.09–0.42; po0.001). In contrast, OS rates
were lower in adherent stage D patients (HR=4.0, 95% CI:
1.67–9.8; po0.001). Adherence to the BCLC recommenda-
tions did not influence OS in patients with stage B or C HCC.
’ DISCUSSION
This study is the first study to examine adherence to BCLC
recommendations for HCC therapy and the corresponding
outcomes in a tertiary center in Brazil. The findings demon-
strate that adherence differs between patients with various
disease stages and that adherence differentially affects
patient survival. Overall, the rates of adherence to BCLC
recommendations were low. A previous prospective study
from a single center in Korea found that only 40% of the 160
consecutive HCC patients were treated according to the
BCLC recommendations (13). Similarly, an Italian multi-
center survey (EpaHCC group) of 536 patients diagnosed
between 2008 and 2011 found that adherence to BCLC
recommendations was not uniform and that 40% of BCLC
stage A patients did not receive curative therapies (14).
Table 1 - Clinical and demographic characteristics of included patients according to Barcelona Clinic Liver Cancer stage, n (%).
Characteristic Stage 0-A (n=130) Stage B (n=85) Stage C (n=115) Stage D (n=34)
Age, yr 60±11 61±12 62±12 67±12
Sex, male 95 (73) 61 (72) 87 (76) 25 (74)
Cirrhosis etiology
HCVw 82 (63) 42 (49) 62 (54) 16 (47)
HBV= 19 (15) 10 (12) 15 (13) 3 (8)
Alcohol 20 (16) 10 (12) 22 (19) 5 (15)
NAFLDy 8 (6) 10 (12) 9 (8) 5 (15)
Other 1 (0) 13 (15) 7 (6) 5 (15)
Ascites 20 (15) 17 (20) 52 (45) 30 (85)
Encephalopathy 10 (8) 7 (8) 16 (14) 16 (47)
Portal hypertension 102 (78) 63 (74) 89 (77) 28 (82)
Child-Pugh
A 103 (79) 64 (75) 56 (49) 3 (9)
B 27 (21) 21 (25) 59 (51) 13 (38)
C 0 0 0 18 (53)
MELDz 10±3 9±3 11±4 13±4
ECOG-PSN
0 130 (100) 85 (100) 27 (23) 2 (6)
1 0 0 71 (62) 5 (15)
2 0 0 17 (15) 10 (29)
42 0 0 0 17 (50)
Number of nodules
1 99 (76) 29 (34) 59 (51) 20 (59)
2 17 (13) 27 (32) 21 (18) 6 (18)
42 14 (11) 29 (34) 35 (41) 8 (23)
Diameter of largest nodule, mm 27±8 58±24 76±50 75±40
Vascular invasion 0 0 37 (32) 4 (12)
Extrahepatic spread 0 0 26 (23) 4 (12)
HCC± within Milan criteria 130 (100) 0 27 (23) 12 (35)
wHCV: Hepatitis C virus; =HBV: Hepatitis B virus; yNAFLD: Nonalcoholic fatty liver disease; zMELD: Model for End-stage Liver Disease score;
NECOG-PS: Eastern Cooperative Oncology Group Performance Status; ± HCC: Hepatocellular carcinoma.
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For BCLC stage 0/A patients, who are candidates for
curative therapies, adherence to BCLC recommendations
was associated with a better survival rate. However, only
45% of these patients received the prescribed therapy, which
is consistent with the results in a previous report (15). Liver
resection and percutaneous ablation were primarily limited
by tumor location, whereas the long wait time hindered
cadaveric-donor liver transplantation. Donor shortage is a
significant problem in Brazil, as the number of cadaveric
donors is B8.4 per million people (pmp). Although the
yearly donation rate has doubled over the past decade, it is
still lower than that in Europe (15 pmp) and the United
States (26 pmp) (16). As there will always be a shortage of
available donors, new strategies to increase the likelihood of
Figure 1 - Adherence to the Barcelona Clinic Liver Cancer (BCLC) staging system according to stage.
Table 2 - Univariate and multivariate analyses of prognostic factors for overall survival.
Variable Univariate Multivariate
HRN (95% CIp) p-value HRN (95% CIp) p-value
Sex 1.04 (0.77–1.40) 0.80 - -
Age (p66 vs 466 yr) 1.36 (1.03–1.79) 0.02 1.71 (1.28–2.28) 0.01
Cirrhosis (yes vs no) 1.48 (0.76–2.88) 0.25 - -
Child-Pugh (B/C vs A) 2.91 (2.20–3.86) o0.01 2.19 (1.52–3.17) o0.01
MELDw (p11 vs 411) 1.84 (1.39–2.42) o0.01 1.07 (1.03–1.12) o0.01
Portal hypertension (positive vs negative) 1.26 (0.90–1.77) 0.17 - -
ECOG-PS= (0 vs X1) 3.03 (2.30–3.88) o0.01 1.54 (1.10–2.15) 0.01
AFPy (p100 vs 4100 ng/mL) 2.74 (2.09–3.60) o0.01 2.84 (2.13–3.8) o0.01
Tumor size (p50 vs 450 mm) 2.85 (2.18–3.74) o0.01 2.07 (1.52–2.82) o0.01
Number of tumors (1 vs X2) 1.61 (1.23–2.11) o0.01 - -
Vascular invasion (yes vs no) 2.85 (1.98–4.11) o0.01 1.67 (1.09–2.47) 0.01
Extrahepatic spread (yes vs no) 4.47 (2.95–6.76) o0.01 2.52 (1.54–4.12) o0.01
BCLCz (B vs 0/A) 2.58 (1.71-3.88) o0.01 - -
BCLCz (C vs 0/A) 5.14 (3.53-7.49) o0.01 - -
BCLCz (D vs 0/A) 7.51 (4.64-12.16) o0.01 - -
wMELD: Model for End-stage Liver Disease score; = ECOG-PS: Eastern Cooperative Oncology Group Performance Status; yAFP: Alpha-fetoprotein;
zBCLC: Barcelona Clinic Liver Cancer; NHR: Hazard ratio; pCI: Confidence interval.
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transplantation should be discussed and developed, parti-
cularly for patients with early-stage HCC, patients with
decompensated liver function, and/or those who are
receiving locoregional therapies for local tumor control.
For patients with intermediate-stage HCC, TACE is con-
sidered the standard treatment (17). The highest adherence to
BCLC recommendations was in patients of this subgroup.
The current definition of intermediate-stage HCC includes a
wide range of patients with heterogeneous tumor burden
and liver function (17,18), which decrease treatment contra-
indications. Due to this heterogeneity, a subclassification by
tumor burden and liver function has been proposed (19,20).
In practice, TACE is commonly prescribed for all patients in
this group due to the possibility of downstaging to meet the
Milan criteria and for subsequent placement on the liver
transplant list. However, our results indicate that adherence
to BCLC recommendations does not influence OS, which is
in contrast to the results of two previous studies that found
better survival of patients with intermediate-stage HCC who
underwent radical therapies, such as liver resection (10,21).
Sorafenib is the treatment of choice for Child-Pugh A or B
patients with vascular invasion, extrahepatic spread, and/or
compromised general status (7). Sorafenib is the recom-
mended treatment for stage C HCC, the group in which we
observed the lowest adherence to BCLC guidelines. Patients
without vascular invasion or extrahepatic spread but with
compromised general status (ECOG-PS 1–2) received treat-
ment according to the size and number of lesions. Despite the
high rate of non-adherence, no difference in survival was
observed compared with that in patients who received the
BCLC-recommended treatment. This finding supports the
reconsideration of treatment decisions when the clinical stage
is not optimal for a given intervention or when it does not
correlate with expected survival benefits (22).
Figure 2 - Continued.
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Importantly, non-adherence to BCLC recommendations
is associated with better survival of patients with terminal-
stage (BCLC D) disease. Although the presence of advanced
cirrhosis (Child-Pugh class C) prevents the application of
potentially curative therapies, patients on the transplant
wait list should be screened for HCC to detect tumors that
exceed conventional criteria and to help define priority
policies for transplantation (7). In BCLC D patients, non-
adherence to BCLC recommendations was limited to those
who could benefit from liver transplantation. In this study,
nine patients were treated, but only two underwent liver
transplantation.
There were a few limitations of the present study. First,
the study only included patients who were referred to one
tertiary hospital, and the findings may thus not be general-
izable to other centers. Second, this study was retrospective
in nature, and this type of study design may be subject to
patient selection bias. For example, patients with a worse
profile may have been unable to receive treatment according
to the BCLC recommendations, which may have resulted in
a worse prognosis. The retrospective design of the study also
does not allow for a comparison with alternative treatment
algorithms.
The BCLC staging system is recognized as a prognostic
tool and a method for treatment allocation. However, in clini-
cal practice, treatment availability is an important considera-
tion during the selection of individual therapies, which should
be performed by a comprehensive multidisciplinary team.
Figure 2 - Overall survival and adherence to the Barcelona Clinic Liver Cancer (BCLC) recommendations. A) Overall survival; B) Survival
according to BCLC stage. Survival according to adherence to BCLC recommendations in C) all stages, D) stage 0/A, E) stage B, F) stage C,
and G) stage D.
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Treatment strategies should focus on the improvement of
the management of HCC patients. This focus is particula-
rly important in those with early-stage disease for whom
adherence to BCLC recommendations is associated with
improved survival. Furthermore, future efforts should be
made to define second- and third-line therapies for HCC
patients according to their response to the first-line treatment
at each stage.
In summary, the rate of adherence to BCLC recommenda-
tions is low, even at a tertiary referral center for HCC therapy
that has access to all treatment modalities. Adherence to the
recommended guidelines positively impacts survival, espe-
cially in patients with early-stage disease.
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